MARC details
| 000 -LEADER |
|---|
| fixed length control field |
07954namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20251231095713.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
251230s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
615.1 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.08.08.Ph.D.2025.Ra.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Rabab Ahmed Mohamed, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Efficacy and safety of early initiation of canagliflozin in patients with acute decompensated heart failure / |
| Statement of responsibility, etc. |
by Rabab Ahmed Mohamed ; Supervision Prof. Dr. Nirmeen Ahmed Sabry, Prof. Dr. Maggie Magdy Abbassi, Prof. Dr. Bassem Zarif Fouad. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
فعالية وسلامة العلاج المبكر بدواء الكاناجليفلوزين في المرضي الذين يعانون من قصور القلب الحاد اللاتعويضي |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
131 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 69-94. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background and Objectives: Initiating sodium-glucose cotransporter 2 <br/>inhibitor empagliflozin early in hospitalized acute decompensated heart failure <br/>(ADHF) patients was found to increase urine output and resulted in shorter hospital <br/>stays, a decrease in heart failure events (HFEs), and an improvement in health-<br/>related quality of life following hospital discharge. However, limited data is <br/>available related to the early initiation of canagliflozin in ADHF patients. This trial <br/>aims to investigate the effectiveness and safety of early initiation of canagliflozin <br/>within 24 hours of hospital admission, in comparison to empagliflozin, in patients <br/>with ADHF presenting with volume overload. <br/>Methods: This was a multicenter, prospective, randomized equivalence trial. <br/>ADHF diabetic and non-diabetic patients were randomized within 24 hours from <br/>hospital admission to either receive 100 mg canagliflozin or 10 mg empagliflozin <br/>in addition to the standardized protocol for intravenous loop diuretics. The primary <br/>outcome was the median daily diuresis during the hospitalization period. <br/>Secondary outcomes during the hospitalization period include diuretic response <br/>(weight change per 40 mg of furosemide), clinical congestion score, dyspnea <br/>assessment, change in level of NT-pro BNP, and hospital stay length. Patients were <br/>followed-up for 90 days post-discharge to assess the level of NT-pro B-NP at day <br/>30 post-hospital discharge, the change in patients 'quality of life as assessed by the <br/>Kansas City cardiomyopathy questionnaire (KCCQ-23) and the development of <br/>heart failure events (HFEs). In addition, safety outcomes, including volume <br/>depletion, renal adverse effects, hypoglycemia, and ketoacidosis, were assessed <br/>throughout the entire study period. <br/>Results: A total of 142 patients were randomized, with 71 patients assigned <br/>to each group. The median daily diuresis during the hospitalization period was <br/>4200 ml in the canagliflozin group, which was statistically equivalent to <br/><br/><br/>Abstract <br/><br/> <br/><br/>VII <br/><br/>empagliflozin (4117 ml) with a difference of 83 ml, which falls within the <br/>predefined equivalence margin (±10% of the median daily diuresis of <br/>empagliflozin; Δ = ±411.7 mL), confirming equivalence via bootstrap TSOT p < <br/>0.001. During hospitalization no difference was observed in diuretic response, <br/>dyspnea score, orthodema congestion score or length of hospital stay. After 30 days <br/>of hospital discharge, the NT-proBNP levels were lower in the canagliflozin <br/>(median, 1098 pg/mL) compared to the empagliflozin groups (median, 1768 <br/>pg/mL). However, this did not reach statistical significance (p = 0.025). Statistical <br/>significance was defined as P-values < 0.0125 to correct for multiple comparisons. <br/>For the analysis of KCCQ-23 domains (KCCQ-Total Symptom Score, KCCQ-<br/>Clinical Summary Score, and KCCQ-Overall Summary Score), no statistically <br/>significant differences in mean changes from baseline to day 90 post hospital <br/>discharge were observed between groups. The incidence of HFEs until the end of <br/>the trial was 16 (23.9%) in the canagliflozin group and 17(27%) in the <br/>empagliflozin group (p = 0.684). There were no significant differences in the <br/>incidence of safety events. <br/>Conclusion: Early initiation of canagliflozin within 24 hours of hospital <br/>admission for patients with ADHF, independent of their diabetes condition, was <br/>equivalent to empagliflozin in diuresis effect. Canagliflozin also resulted in <br/>comparable decreases in congestion and NT-proBNP levels, lowering HF events <br/>and enhancing patients' quality of life but the study was not powered for the <br/>secondary outcomes. These findings suggest that the initiation of canagliflozin <br/>could be a part of usual care for hospitalized ADHF patients and an alternative to <br/>empagliflozin without safety concerns. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
كانت هذه دراسة معادلة، عشوائية، متعددة المراكز، استشرافية ، هدفت إلى تقييم البدء المبكر بعقار كاناجليفلوزين مقارنة بإمباغليفلوزين في 142 مريضًا أدخلوا إلى المستشفى بسبب قصور القلب الحاد اللاتعويضي (ADHF) مع وجود احتباس سوائل. خلال أول 24 ساعة من دخول المستشفى، تم توزيع المرضى عشوائيًا بغض النظر عن إصابتهم بالسكري لتلقّي إما 100 ملغ من كاناجليفلوزين أو 10 ملغ من إمباغليفلوزين، مع العلاج القياسي بمدرات البول الحلقية الوريدية.<br/>كان المعيار الأساسي للدراسة هو متوسط الإدرار البول اليومي خلال فترة الاستشفاء، وقد أظهرت النتائج تكافؤًا إحصائيًا بين المجموعتين (كاناجليفلوزين: 4200 مل؛ إمباغليفلوزين: 4117 مل؛ p < 0.001 ). لم تُسجل فروق ذات دلالة إحصائية في النتائج الثانوية داخل المستشفى، بما في ذلك الاستجابة لمدرات البول، درجة الاحتقان الوذمي، أو مدة الإقامة في المستشفي. بعد مرور 30 يومًا من الخروج من المستشفى، كانت مستويات NT-proBNP أقل في مجموعة الكاناجليفلوزين مقارنةً بمجموعة الإمباغليفلوزين، إلا أن هذا الفرق لم يصل إلى مستوى الدلالة الإحصائية (p = 0.025). كذلك، كانت نتائج جودة الحياة ومعدل الأحداث المرتبطة بقصورعضلة القلب خلال 90 يومًا متقاربة بين المجموعتين . كما لم تُلاحظ فروق تُذكر في معدلات أحداث السلامة بين المجموعتين. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Clinical pharmacology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
الصيدلة الإكلينيكية |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Acute decompensated heart failure |
| -- |
Canagliflozin |
| -- |
Empagliflozin |
| -- |
Sodium-glucose cotransporter 2 inhibitor |
| -- |
قصور القلب الحاد اللا تعويضي |
| -- |
كاناجليفلوزين |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Nirmeen Ahmed Sabry |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Maggie Magdy Abbassi |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bassem Zarif Fouad |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2025 |
| Supervisory body |
Nirmeen Ahmed Sabry |
| -- |
Maggie Magdy Abbassi |
| -- |
Bassem Zarif Fouad |
| Universities |
Cairo University |
| Faculties |
Faculty of Pharmacy |
| Department |
Department of Clinical Pharmacy |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |